Rhabdomyosarcoma, a fatal cancer in children, requires innovative treatments. This recent study introduces an effective genetic screening method aimed at identifying genes that promote the transition of rhabdomyosarcoma cells into normal muscle cells. The method facilitated the discovery of NF-Y, a significant protein influencing the behavior of rhabdomyosarcoma. Through the application of CRISPR-based genetic manipulation, the researchers achieved the conversion of rhabdomyosarcoma cells into differentiated muscle cells, elucidating the underlying mechanism. Due to the prevalence of cell differentiation deficiencies in various human sarcomas, this approach might have broad applicability in the investigation of these tumors. Moreover, the findings suggest NF-Y as a prospective target for the development of differentiation therapy for rhabdomyosarcoma.1

Read the full study here.

References

  1. Sroka, M. W., Skopelitis, D. S., Vermunt, M. W., Preall, J., Demerdash, O. E., De Almeida, L. M. N., Chang, K., Utama, R., Gryder, B. E., Caligiuri, G., Ren, D., Nalbant, B., Milazzo, J. P., Tuveson, D. A., Dobin, A., Hiebert, S. W., Stengel, K. R., Mantovani, R., Khan, J., . . . Vakoc, C. R. (2023). Myo-differentiation reporter screen reveals NF-Y as an activator of PAX3–FOXO1 in rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 120(36). https://doi.org/10.1073/pnas.2303859120

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred